/RNTX
RNTX Stock - Rein Therapeutics Inc.
Healthcare|Medical - PharmaceuticalsNASDAQ
$1.42+10.08%
+$0.13 (+10.08%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+322.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RNTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.41 – $1.43
TARGET (TP)$6.00
STOP LOSS$1.31
RISK/REWARD1:41.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.27
52W High$3.50
52W Low$1.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-65,112,000 | $-16,276 | $-27,647 | $-26,605 | $-20,496 |
| Net Income | $-62,883,000 | $-15,732 | $-27,329 | $-26,164 | $-21,157 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.51 | $-3.42 | $-6.02 | $-5.89 | $-0.00 |
Company Overview
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 533.8% Upside
Now
$8
Low
$9
Average
$10
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 22nd 2025 | H.C. Wainwright | Initiation | Buy | $10 |
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $8 |
Earnings History & Surprises
RNTXBeat Rate
20%
Last 10 quarters
Avg Surprise
-195.1%
EPS vs Estimate
Beats / Misses
2/8
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q4 23
-840.0%
$-1.54vs$-0.16
Q1 24
-512.0%
$-0.86vs$-0.14
Q3 24
-80.0%
$-0.45vs$-0.25
Q4 24
-8.0%
$-0.27vs$-0.25
Q4 24
-310.7%
$-1.89vs$-0.46
Q2 25
-85.7%
$-0.26vs$-0.14
Q3 25
-27.3%
$-0.28vs$-0.22
Q4 25
+12.5%
$-0.21vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.22 | $-0.28 | -27.3% | ✗ MISS |
Q2 2025 | Apr 7, 2025 | $-0.14 | $-0.26 | -85.7% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | $-0.46 | $-1.89 | -310.7% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.25 | $-0.45 | -80.0% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | $-0.14 | $-0.86 | -512.0% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | $-0.16 | $-1.54 | -840.0% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.20 | $-0.40 | -101.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.40 | $-0.39 | +1.6% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.60 | — | — | — |
Q1 2023 | Mar 20, 2023 | $-1.30 | — | — | — |
Latest News
Rein Therapeutics Q3 EPS $(0.21) Beats $(0.23) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 03:15 PM
Rein Therapeutics Reports Preclinical Results For Inhaled LTI-03 In IPF, Showing Safety And Biomarker Reductions
📈 PositiveBenzinga•Nov 6, 2025, 12:37 PM
Rein Therapeutics Cleared To Resume Phase 2 Study Of LTI-03 For Idiopathic Pulmonary Fibrosis
📈 PositiveBenzinga•Nov 3, 2025, 12:36 PM
The FDA Has Lifted The Full Clinical Hold On Rein Therapeutics' Phase 2 RENEW Trial Evaluating LTI-03 In Patients With Idiopathic Pulmonary Fibrosis
📈 PositiveBenzinga•Nov 3, 2025, 12:35 PM
Rein Therapeutics shares are trading higher after the company received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
📈 PositiveBenzinga•Nov 3, 2025, 12:34 PM
Rein Therapeutics Receives Authorization From EMA To Initiate Phase 2 "RENEW" Clinical Trial Of LTI-03 For Treatment Of Idiopathic Pulmonary Fibrosis
📈 PositiveBenzinga•Oct 9, 2025, 11:32 AM
Rein Therapeutics Announced FDA Feedback On Clinical Hold For U.S. Phase 2 RENEW Trial Of LTI-03 In IPF; MCH/H Findings Deemed Not Dose-Limiting For 24-Week Protocol Up To 10 Mg/Day
📈 PositiveBenzinga•Sep 22, 2025, 12:07 PM
HC Wainwright & Co. Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $10
📈 PositiveBenzinga•Sep 22, 2025, 10:14 AM
Rein Highlights Translational Data Demonstrating LTI-03's Broad Anti-Fibrotic Activity Without Cell Damage
📈 PositiveBenzinga•Sep 17, 2025, 11:43 AM
Rein Therapeutics Files Prospectus Related To Offer And Sale Of Up To 10M Shares Of Common Stock By Selling Stockholder
➖ NeutralBenzinga•Sep 3, 2025, 09:17 PM
Brookline Capital Downgrades Rein Therapeutics to Hold
📉 NegativeBenzinga•Aug 19, 2025, 02:17 PM
UK MHRA Authorizes Rein Therapeutics To Initiate Phase 2 "RENEW" Clinical Trial Of LTI-03, For Idiopathic Pulmonary Fibrosis
📈 PositiveBenzinga•Aug 19, 2025, 12:12 PM
Frequently Asked Questions about RNTX
What is RNTX's current stock price?
Rein Therapeutics Inc. (RNTX) is currently trading at $1.42 per share. The stock has moved +10.08% today.
What is the analyst price target for RNTX?
The average analyst price target for RNTX is $6.00, based on 1 analyst.
What sector is Rein Therapeutics Inc. in?
Rein Therapeutics Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is RNTX's market cap?
Rein Therapeutics Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does RNTX pay dividends?
No, Rein Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BEAT
HeartBeam, Inc.
$3.10
Mkt Cap: $0.1B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
NOTV
Inotiv, Inc.
$0.67
Mkt Cap: $0.0B
QNTM
Quantum BioPharma Ltd.
$8.89
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
YI
111, Inc.
$3.69
Mkt Cap: $0.0B
Explore stocks similar to RNTX for comparison